



MSN/2023/066

Cisplatin 50mg/50ml and 100mg/100ml concentrate for solution for infusion vials (Pfizer)

Tier 2 - medium *

Date of issue: 13 July 2023 Link: Medicines Supply Tool

Summary

- Pfizer is out of stock of cisplatin 50mg/50ml concentrate for solution for infusion vials and will be out of stock of the 100mg/100ml concentrate for solution for infusion vials from the end of July 2023. Resupply is expected mid to end of September 2023.
- Accord remains in stock of both strengths and can continue to supply their contracted region (London North & East of England (DLN) but cannot support the demand from non-contracted regions (North West (DNW), East Midlands, West Midlands, South West and South-Central regions (CESW) & South London, South East Coast, North East, and Yorkshire & Humber (LSNE)) during this period.
- Specialist importers have indicated that unlicensed imports of cisplatin 50mg/50ml and 100mg/100ml concentrate for solution for infusion vials can be sourced, lead times vary.
- Supplies from commercial compounders will remain available but are not able to increase capacity or accept new customers during this period. Any new or increased ordering will be challenged.

Actions Required

NHS provider pharmacy procurement teams in **Pfizer (CESW, LSNE & DNW)** contracted regions should:

- urgently place orders for unlicensed imports (see supporting information) to meet the needs of patients;
- work with the pharmacy aseptic and quality assurance leads in Trusts to be ready to use unlicensed imports in aseptic units on receipt; and
- work with their pharmacy aseptic lead to ensure appropriate mitigations are put in place to minimise the risk of product confusion and dosing errors if Trusts are likely to have multiple unlicensed products in use within the organisation at the same time.

NHS provider pharmacy procurement teams in **Accords (DLN)** contracted region should:

• continue to place orders in line with forecasted demand. Any over ordering will be challenged.

Supporting Information

Guidance on ordering and prescribing unlicensed imports

- The following specialist importers have confirmed they can source unlicensed Cisplatin 50mg/50ml and 100mg/100ml concentrate for solution for infusion vials (please note there may be other companies that can also source supplies):
 - Clinigen Healthcare*
 - o Orifarm
 - o Qmed Pharma
 - o Smartway*
 - o Target Healthcare
- * Specialist importer has applied for MHRA letter of no objection.
 - Any decision to prescribe an unlicensed medicine must consider the relevant guidance and NHS
 Trust or local governance procedures. Please see the links below for further information:
 - The supply of unlicensed medicinal products, Medicines and Healthcare products Regulatory Agency (MHRA)
 - <u>Professional Guidance for the Procurement and Supply of Specials</u>, Royal Pharmaceutical Society
 - o <u>Prescribing unlicensed medicines</u>, General Medical Council (GMC),

Please see the following links for further information:

- BNF Cisplatin
- SmPC Cisplatin

Enquiries

Enquiries from NHS Trusts in England should in the first instance be directed to your Regional Pharmacy Procurement Specialist, who will escalate to national teams if required.

REGION	Full Name	Email
Midlands	Andi Swain (East Midlands)	andi.swain@nhs.net
	Diptyka Hart (West Midlands)	Diptyka.Hart@uhb.nhs.uk
East of England	James Kent	james.kent@nhs.net
London	Jackie Eastwood	jacqueline.eastwood@gstt.nhs.uk
North East and	David Allwood (Yorkshire)	davidallwood@nhs.net
Yorkshire		
North West	Richard Bateman	richard.bateman2@nhs.net
South East	Alison Ashman	Alison.Ashman@berkshire.nhs.uk
South West	Danny Palmer	danny.palmer@uhbw.nhs.uk

Scotland

nss.nhssmedicineshortages@nhs.scot

Wales

MedicinesShortages@gov.wales

Northern Ireland

RPHPS.Admin@northerntrust.hscni.net

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN/2023/066 Email: DHSCmedicinesupplyteam@dhsc.gov.uk.